CLINICAL STUDY ON AT-2266

• MURAYAMA YUMIKO

  Department of Internal Medicine, National Kasumigaura Hospital

• OKANO REIKO

  Department of Internal Medicine, National Kasumigaura Hospital

• HAYAKAWA MASAKATSU

  Department of Internal Medicine, National Kasumigaura Hospital

• ADACHI MASANORI

  Department of Internal Medicine, National Kasumigaura Hospital

• IMATAKA KUNIO

  Department of Internal Medicine, National Kasumigaura Hospital

• KAWAI MIEKO

  Department of Internal Medicine, National Kasumigaura Hospital

• NAKANO MASATO

  Department of Internal Medicine, National Kasumigaura Hospital

• OKAYAMA KENICHI

  Department of Internal Medicine, National Kasumigaura Hospital

• TAKIZUKA HISASHI

  Department of Internal Medicine, National Kasumigaura Hospital

• KATSU MASATAKA

  Department of Internal Medicine, National Kasumigaura Hospital

Bibliographic Information

Other Title

• AT-2266の臨床的検討

Abstract

AT-2266, a newly developed pyridonecarboxylic acid derivative, was administered to 7 patients with respiratory tract infections and 2 patients with urinary tract infections. The dosage was 600 to 900 mg/ day given in divided doses three times daily for 5 to 14 days. The clinical response was excellent in 1 case, good in 6 cases, and fair in 2 cases. The success rate was 77.8%.<BR>Neither side effects nor abnormal laboratory findings were found.

Journal

• CHEMOTHERAPY

  CHEMOTHERAPY 32 (Supplement3), 399-402, 1984

  Japanese Society of Chemotherapy

Details

• CRID: 1390282681259384576
• NII Article ID: 130004194360
• DOI: 10.11250/chemotherapy1953.32.supplement3_399
• ISSN: 18845894
• ISSN: 00093165
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed